Hospital Universitari General De Catalunya — Clinical Trial Site

71 Registered trials

25 Currently recruiting

Organisation

Hospital Universitari General De Catalunya

Location

Sant Cugat Del Valles, Spain

Identifier

ORG-100042937

Address

Carrer Pedro I Pons 1, 08195, Spain

Departments

#40280:Neurology Service
034029: Oncología
3804: Oftalmología
7003:
9007: Neurology
Department of Pediatrics
Department of Reproductive Medicine
ESP5: Oftalmología
Haematology
Medical Oncology
N/A
Neurología
Neurology
Neurology Department
Obstetricia
Oncología
Oncología Medica
Oncology
Oncology Department
Ophtalmology
Ophthalmology
Pediatric Unit
Servicio de Neurología
Servicio de Oftalmologia
Unidad Investigacion clinica
Unitat d’Investigacio Clinica
Unitat d’Investigacio Clinica (Neurology)

Clinical trials at this site (71)

Search interface

Intranasal nafarelin compared to subcutaneous triptorelin for triggering final oocyte maturation in ovarian stimulation: a non-inferiority r… Pending

2024-516621-31-00 Infertility 6
A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerabi… Pending

2025-522582-30-00 Alzheimer’s Disease 1
The impact of ovarian stimulation with hMG on embryo quality in advanced age women. A randomized controlled trial Pending

2025-524761-25-00 infertility 6
An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518006-40-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-13
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheime… Recruiting

2023-509807-34-00 Early Alzheimer’s Disease (Mild Cognitive Impairment an 4 2024-08-12
A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in… Recruiting

2022-501152-28-00 Breast Cancer 4 2022-12-21
An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients wi… Recruiting

2025-524367-20-00 Adult patients with primary mitochondrial disease 4 2026-06-30
A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participant… Recruiting

2025-523481-24-00 Participants with Progressive Supranuclear Palsy Richar 5 2026-06-24
A clinical trial to learn more about the effects of FWY003 in people with geographic atrophy associated with age-related macular degeneratio… Recruiting

2025-523704-77-00 Geographic atrophy secondary to age-related macular deg 4 2026-06-04
SIE-1 Recruiting

2025-523269-31-00 Hormone receptor-positive early breast cancer in post-m 3 2026-06-02
First-in-Human Study of RO7812653 Recruiting

2025-522101-37-00 Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cogn 1 2026-02-17
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease Recruiting

2024-516966-12-00 Alzheimer’s disease 4 2026-02-13
Effect of Semaglutide on embryo quality in overweight and obese patients undergoing In Vitro Fertilization. A Randomized Controlled Trial Recruiting

2025-522525-34-00 Infertility 6 2026-01-19
A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting

2025-522683-32-00 Early-Stage Parkinson’s Disease (PD) 5 2026-01-15
A Prospective, Open-Label, Randomized, Interventional Study to Evaluate the Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol … Recruiting

2025-522004-24-00 iron deficient 11 2025-12-11
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520746-30-00 Mild to moderate Alzheimer’s Disease 5 2025-11-18
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis Recruiting

2024-515979-35-00 Generalized Myasthenia Gravis 5 2025-11-13
A Study to Determine Safety and Long-Term Effectiveness of Faricimab in Participants with Age-Related Macular Degeneration Recruiting

2024-517545-13-00 Neovascular Age-Related Macular Degeneration 11 2025-06-04
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 … Recruiting

2022-500747-21-00 Geographic Atrophy 4 2025-02-27
A Phase IV, Multicenter, Open-label, Single-arm Study to Evaluate the Safety of Almagate in Pregnant Women With Heartburn and Reflux, and Pe… Recruiting

2024-515381-14-00 heartburn and or reflux 6 2024-11-20
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA) Recruiting

2023-504472-24-00 Early Idiopathic Parkinson’s disease (PD) 4 2024-03-19